<DOC>
	<DOCNO>NCT02372175</DOCNO>
	<brief_summary>To evaluate effectiveness candidate dengue vaccine formulation , prudent develop appropriate challenge model . To end , first-in-human study examine safety effectiveness Dengue 1 Live Virus Human Challenge ( DENV-1-LVHC ) product assess ability virus strain elicit uncomplicated dengue-like illness .</brief_summary>
	<brief_title>Assessment Dengue-1-Virus-Live Virus Human Challenge - ( DENV-1-LVHC ) Virus Strain</brief_title>
	<detailed_description />
	<mesh_term>Dengue</mesh_term>
	<criteria>1 . Healthy , male nonpregnant , nonlactating female 2 . Age 1845 3 . Ability willingness sign inform consent 4 . Passing score comprehension test would 75 % , 3 attempt 5 . Available study period 6 . Willing use contraception duration study . 7 . Provide consent release medical history record primary care physician , college university , urgent care emergency room visit 1 . Female : pregnant lactate 2 . Heavy menstrual bleeding within last 6 monthsmenstrual period last longer 6 day , require 5 pad tampon per day . 3 . Female subject use intrauterine device ( IUD ) Mirena® 4 . Female subject fibroid uterine polyp , endometriosis , dysmenorrhea , adenomyosis , uterine scarring ( e.g . D &amp; C ) 5 . Blood test confirm infection human immunodeficiency virus 1 ( HIV1 ) , hepatitis C , hepatitis B surface antigen , flavi virus ( FV ) include dengue fever , West Nile , Yellow Fever , Japanese encephalitis . 6 . Diabetes , chronic obstructive pulmonary disease ( COPD ) , peptic ulcer disease ( PUD ) , coronary artery disease ( CAD ) 7 . Known suspected congenital acquire immunodeficiency ; receipt immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month ; longterm systemic corticosteroid therapy ( prednisone equivalent 2 consecutive week within past 3 month ) 8 . Immediate family member ( e.g . parent , sibling , child ) current , history immunodeficiency autoimmune disease 9 . Current history autoimmune disease 10 . History Guillain Barré syndrome ( GBS ) 11 . Any history FV infection FV vaccination ; plan FV vaccination , outside study protocol , study period 12 . History Bipolar Disorder , Schizophrenia , hospitalization past year mental health disorder , psychiatric condition , opinion investigator prevents subject participate study . 13 . Planned travel study period ( 180 day ) would interfere ability complete study visit 14 . Recent ( past 4 week ) travel dengue endemic area . These potential subject may eligible enrollment minimum 4 week later 15 . Any laboratory abnormality test specify Table 19 Table 20 protocol . Note : laboratory test repeat screen physician believe 1 ) think normal variant healthy state 2 ) suspect laboratory error 16 . Significant screen physical examination abnormality discretion investigator 17 . Women intend become pregnant men intend father child study period ( approximately 6 month ) 18 . Hives , shortness breath , swell lip throat , hospitalization relate previous vaccination allergy specific medications/animals antigen may virus preparation include : shellfish allergy , fetal bovine serum , Lglutamine , neomycin streptomycin 19 . Planning donate blood 1 year follow inoculation dengue 20 . Participation plan participation another vaccine , drug , medical device , medical procedure clinical trial 4 week prior trial , trial , 6 month follow inoculation clinical trial 21 . Beliefs bar administration blood product transfusion 22 . Positive urine screen cocaine , amphetamine , opiates 23 . Currently take Methadone Suboxone 24 . Currently take anticoagulant medication , aspirin nonsteroidal antiinflammatory drug ( NSAIDs ) 25 . Chronic migraine headache , define 15 headache day per month 3 month period 8 migrainous , absence medication use 26 . Chronic medical condition , opinion investigator impact subject safety .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Dengue</keyword>
</DOC>